Affiliation:
1. College of Medical Science, China Three Gorges University, Yichang 443002, China
Abstract
Background:
Long non-coding RNA (lncRNA) breast cancer anti-estrogen resistance 4 (BCAR4) is
a characterized oncogenic lncRNA in different cancers. This review is dedicated to summarize various molecular
mechanisms of BCAR4 and demonstrate that the biological functions exerted by BCAR4 are good entry
points for therapy.
Methods:
The molecular mechanism of BCAR4 acting on tumors is summarized by reviewing PubMed.
Results:
The expression of lncRNA BCAR4 is abnormally increased in all kinds of tumors, including colorectal
cancer, prostate cancer, bladder cancer, gastric cancer, chondrosarcoma, glioma, breast cancer, glioma, gastric
cancer, liver cancer, cervical cancer, lung cancer, etc. Besides, BCAR4 mediates multiple processes involved
in carcinogenesis, including proliferation, invasion, anti-apoptosis, migration.
Conclusion:
BCAR4 may show great clinical value in this direction as a therapeutic cancer target.
Funder
Central government guides the special funds for the development of local science and technology
Health commission of Hubei Province scientific research project in China
National Natural Science Foundation of China
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献